NOZINAN SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE)

제공처:

NEURAXPHARM ARZNEIMITTEL GMBH

ATC 코드:

N05AA02

INN (International Name):

LEVOMEPROMAZINE

복용량:

25MG

약제 형태:

SOLUTION

구성:

METHOTRIMEPRAZINE (METHOTRIMEPRAZINE HYDROCHLORIDE) 25MG

관리 경로:

INTRAMUSCULAR

패키지 단위:

15G/50G

처방전 유형:

Prescription

치료 영역:

PHENOTHIAZINES

제품 요약:

Active ingredient group (AIG) number: 0134080002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2000-11-06

제품 특성 요약

_Page 1 of 31_
_NOZINAN (Methotrimeprazine Hydrochloride Injection, USP)_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NOZINAN®
Methotrimeprazine Hydrochloride Injection, USP
Solution, 25 mg/mL methotrimeprazine as methotrimeprazine
hydrochloride,
intravenous and intramuscular
USP
Neuroleptic
Neuraxpharm Arzneimittel GmbH
Elisabeth-Selbert-Str. 23,
40764 Langenfeld
Germany
Imported and distributed by
Xediton Pharmaceuticals Inc,
2020 Winston Park Drive, Suite 402
Oakville, Ontario L6H 6X7
Submission Control Number: 279974
Date of Initial Authorization:
NOV 15, 2023
_ _
_NOZINAN (Methotrimeprazine Hydrochloride Injection, USP) _
_Page 2 of 31_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS, 1.1 Pediatrics
09/2022
1 INDICATIONS, 1.2 Geriatrics
09/2022
2 CONTRAINDICATIONS
09/2022
3 SERIOUS WARNNGS AND PRECAUTIONS BOX
09/2022
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
09/2022
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
09/2022
7 WARNINGS AND PRECAUTIONS
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1 Pediatrics
......................................................................................................................
4
1.2 Geriatrics
......................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
....................